Approval Time : Sept. 24, 2018
Direct Target : PI3KCG,PI3KCD
Drug Type : Multi-target inhibitor
Indications : Duvelisib was approved for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.
Mechanism Of Action :
Duvelisib is an inhibitor of PI3K with inhibitory activity predominantly against PI3K-δ and PI3K-γ isoforms expressed in normal and malignant B-cells. Duvelisib induced growth inhibition and reduced viability in cell lines derived from malignant B-cells and in primary CLL
tumor cells. Duvelisib inhibits several key cell-signaling pathways, including B-cell receptor signaling and CXCR12-mediated chemotaxis of malignant B-cells. Additionally, duvelisib inhibits CXCL12-induced T cell migration and M-CSF and IL-4 driven M2 polarization of
macrophages.
Dosage : The recommended dose of duvelisib in the current indications is 25 mg orally twice daily.
Related Targets and Diseases
| Drug Name |
Gene |
|
Disease |
|
Negative Genotypes |
Drug Brand |
|
Drug Type |
|
